Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases
Sign Up to like & getrecommendations! Published in 2018 at "AntiCancer Research"
DOI: 10.21873/anticanres.13014
Abstract: Background/Aim: Anti-EGFR antibodies or bevacizumab comprise first-line treatment for patients with RAS wild-type colorectal liver metastases (CLM). Which marker better predicts efficacy, early tumor shrinkage or morphologic response, still remains unclear. Patients and Methods: We… read more here.
Keywords: morphologic response; tumor shrinkage; colorectal liver;